Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma

Asia-Pacific Journal of Clinical Oncology

Volumn 6, Issue 2, 2010, Pages 80-88

  Shao, Yu Yun ^a,b,c   Huang, Chun Chieh ^a,c   Liang, Po Chin ^a,c   Lin, Zhong Zhe ^a,b,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b Department of Oncology ^*  (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Chemotherapy; Hepatic arterial infusion; Hepatocellular carcinoma

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; MACROSALB TC 99M; MITOMYCIN C; PEGINTERFERON ALPHA; SORAFENIB; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANGIOGRAPHY; ANOREXIA; ARTERY DISSECTION; ARTERY OCCLUSION; ARTERY PUNCTURE; ARTIFICIAL EMBOLISM; AXILLARY ARTERY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CATHETER COMPLICATION; CATHETER INFECTION; CATHETERIZATION; CELIAC ARTERY; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMORAL ARTERY; FIRST PASS EFFECT; FLOW RATE; FLUOROSCOPY; GASTRITIS; GASTRODUODENAL ARTERY; HEMATOMA; HEPATIC ARTERY; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; INFUSION PUMP; LAPAROTOMY; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER METASTASIS; MINIPUMP; NAUSEA; NEUTROPENIA; PATIENT SELECTION; PEPTIC ULCER; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROPER HEPATIC ARTERY; REVIEW; SHUNTING; SUBCLAVIAN ARTERY; SUPERIOR MESENTERIC ARTERY; SURVIVAL RATE; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; CARCINOMA, HEPATOCELLULAR; INTRAARTERIAL DRUG ADMINISTRATION; LIVER NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS;

EID: 77954139207     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2010.01287.x     Document Type: Review

References (69)

1. GLOBOCAN 2002. http://www-dep.iarc.fr, International Agency for Cancer Research, cited 23 Apr 2007]. Available from:
2. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002, 122:1609-19.
3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-42.
4. Cheng AL, Yeh KH, Fine RL. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma. Hepatogastroenterology 1998, 45:1955-60.
5. Cusnir M, Patt YZ. Novel systemic therapy options for hepatocellular carcinoma. Cancer J 2004, 10:97-103.
6. Hsu C, Cheng JC, Cheng AL. Recent advances in non-surgical treatment for advanced hepatocellular carcinoma. J Formos Med Assoc 2004, 103:483-95.
7. Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer 2005, 103:756-62.
8. Yeo W, Mok TS, Zee B. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005, 97:1532-8.
9. Louafi S, Boige V, Ducreux M. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007, 109:1384-90.
10. Qamar AA, Grace ND. Abnormal hematological indices in cirrhosis. Can J Gastroenterol 2009, 23:441-5.
11. Espanol I, Gallego A, Enriquez J. Thrombocytopenia associated with liver cirrhosis and hepatitis C viral infection: role of thrombopoietin. Hepatogastroenterology 2000, 47:1404-6.
12. Mehrotra TN. Pathogenesis of anemia in cirrhosis of liver. Indian J Med Sci 1957, 11:86-91.
13. Cheng AL, Kang YK, Chen Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
14. Llovet JM, Ricci S, Mazzaferro V. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-90.
15. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954, 30:969-77.
16. Ackerman NB. The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery 1974, 75:589-96.
17. Sigurdson ER, Ridge JA, Kemeny N, Daly JM. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 1987, 5:1836-40.
18. Ensminger WD, Rosowsky A, Raso V. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res 1978, 38:3784-92.
19. Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984, 2:498-504.
20. Grage TB, Vassilopoulos PP, Shingleton WW. Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: a Central Oncology Group study. Surgery 1979, 86:550-5.
21. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987, 206:685-93.
22. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987, 107:459-65.
23. Hohn DC, Stagg RJ, Friedman MA. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989, 7:1646-54.
24. Martin JK, O'Connell MJ, Wieand HS. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990, 125:1022-7.
25. Wagman LD, Kemeny MM, Leong L. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990, 8:1885-93.
26. Rougier P, Laplanche A, Huguier M. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992, 10:1112-18.
27. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994, 344:1255-60.
28. Kerr DJ, McArdle CS, Ledermann J. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 2003, 361:368-73.
29. Barone RM, Byfield JE, Goldfarb PB, Frankel S, Ginn C, Greer S. Intra-arterial chemotherapy using an implantable infusion pump and liver irradiation for the treatment of hepatic metastases. Cancer 1982, 50:850-62.
30. Buchwald H, Grage TB, Vassilopoulos PP, Rohde TD, Varco RL, Blackshear PJ. Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump. Cancer 1980, 45:866-9.
31. Yoshikawa M, Ebara M, Nakano T, Minoyama A, Sugiura N, Ohto M. Percutaneous transaxillary catheter insertion for hepatic artery infusion chemotherapy. AJR Am J Roentgenol 1992, 158:885-6.
32. Iwamiya T, Sawada S, Ohta Y. Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol 1994, 33:S134-8. Suppl.
33. Yasui M, Nonami T, Kurokawa T. Effects of hepatic arterial infusion chemotherapy on unresectable or recurrent hepatocellular carcinoma. Cancer Chemother Pharmacol 1994, 33:S139-41. Suppl.
34. Kusano S, Katayama M, Uematsu M. Intraarterial infusion of dibutyryl cyclic adenosine monophosphate plus mitomycin C for unresectable hepatocellular carcinoma: long-term survival and response to tumor growth inhibition. Acad Radiol 1995, 2:286-92.
35. Hayashi N, Sakai T, Kitagawa M, Kimoto T, Ishii Y. Percutaneous long-term arterial access with implantable ports. Direct subclavian approach with US. Eur J Radiol 1998, 26:304-8.
36. Ando E, Tanaka M, Yamashita F. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002, 95:588-95.
37. Lai YC, Shih CY, Jeng CM. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2003, 9:2666-70.
38. Inaba Y, Arai Y, Matsueda K, Takeuchi Y, Aramaki T. Right gastric artery embolization to prevent acute gastric mucosal lesions in patients undergoing repeat hepatic arterial infusion chemotherapy. J Vasc Interv Radiol 2001, 12:957-63.
39. Chung YH, Song IH, Song BC. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000, 88:1986-91.
40. Itamoto T, Nakahara H, Tashiro H. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol 2002, 80:143-8.
41. Obi S, Yoshida H, Toune R. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006, 106:1990-7.
42. Minoyama A, Yoshikawa M, Ebara M, Saisho H, Sugiura N, Ohto M. Study of repeated arterial infusion chemotherapy with a subcutaneously implanted reservoir for advanced hepatocellular carcinoma. J Gastroenterol 1995, 30:356-66.
43. Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 1998, 55:39-47.
44. Cheong JY, Lee KM, Cho SW. Survival benefits of intra-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol Res 2005, 32:127-33.
45. Sumie S, Yamashita F, Ando E. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. AJR Am J Roentgenol 2003, 181:1327-34.
46. Yamasaki T, Kimura T, Kurokawa F. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol 2005, 40:70-8.
47. Lin CP, Yu HC, Cheng JS. Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced hepatocellular carcinoma. J Chin Med Assoc 2004, 67:602-10.
48. Liang HL, Huang JS, Lin YH, Lai KH, Yang CF, Pan HB. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma by placing a temporary catheter via the subclavian route. Acta Radiol 2007, 48:734-40.
49. Nagai H, Kanayama M, Higami K. Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. World J Gastroenterol 2007, 13:280-4.
50. Park JY, Ahn SH, Yoon YJ. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007, 110:129-37.
51. Kajanti M, Pyrhonen S, Mantyla M, Rissanen P. Intra-arterial and intravenous use of 4′ epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison. Am J Clin Oncol 1992, 15:37-40.
52. Yoshikawa M, Saisho H, Ebara M. A randomized trial of intrahepatic arterial infusion of 4′-epidoxorubicin with Lipiodol versus 4′-epidoxorubicin alone in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 1994, 33:S149-52. Suppl.
53. Ikeda M, Okusaka T, Ueno H. Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis. Oncology 2007, 72:188-93.
54. Ishikawa T, Imai M, Kamimura H. Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. World J Gastroenterol 2007, 13:5465-70.
55. Sangro B, Rios R, Bilbao I. Efficacy and toxicity of intra-arterial cisplatin and etoposide for advanced hepatocellular carcinoma. Oncology 2002, 62:293-8.
56. Enjoji M, Morizono S, Kotoh K. Re-evaluation of antitumor effects of combination chemotherapy with interferon-alpha and 5-fluorouracil for advanced hepatocellular carcinoma. World J Gastroenterol 2005, 11:5685-7.
57. Kasai K, Kuroda H, Ushio A, Sawara K, Takikawa Y, Suzuki K. Evaluation of newly developed combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma with portal venous invasion: preliminary results. Hepatol Res 2009, 39:117-25.
58. Katamura Y, Aikata H, Takaki S. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. J Gastroenterol 2009, 44:492-502..
59. Kuroda M, Kobayashi Y, Urawa N. Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma. Hepatogastroenterology 2007, 54:518-21.
60. Ota H, Nagano H, Sakon M. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005, 93:557-64.
61. Takaki-Hamabe S, Yamasaki T, Saeki I. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: is the addition of subcutaneous interferon-alpha-2b beneficial? Hepatol Res 2009, 39:223-30.
62. Mawatari H, Kirikoshi H, Yoneda M. Effective treatment for advanced hepatocellular carcinoma with portal venous invasion using a combination therapy of intra-arterial 5-fluorouracil and subcutaneous pegylated-interferon-alpha-2b. Hepatogastroenterology 2008, 55:1776-7.
63. Nagano H, Sakon M, Eguchi H. Hepatic resection followed by IFN-alpha and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. Hepatogastroenterology 2007, 54:172-9.
64. Sakon M, Nagano H, Dono K. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002, 94:435-42.
65. Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T, Kakkos SK. Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma. Hepatogastroenterology 1999, 46:1122-5.
66. Charnsangavej C, Kirk IR, Dubrow RA. Arterial complications from long-term hepatic artery chemoinfusion catheters: evaluation with CT. AJR Am J Roentgenol 1993, 160:859-64.
67. Toyoda H, Nakano S, Kumada T. The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 1995, 52:295-9.
68. Arai Y, Inaba Y, Takeuchi Y, Ariyoshi Y. Intermittent hepatic arterial infusion of high-dose 5-FU on a weekly schedule for liver metastases from colorectal cancer. Cancer Chemother Pharmacol 1997, 40:526-30.
69. Kaplan WD, Come SE, Takvorian RW. Pulmonary uptake of technetium 99m macroaggregated albumin: a predictor of gastrointestinal toxicity during hepatic artery perfusion. J Clin Oncol 1984, 2:1266-9.